He aha te Whakaaetanga a Isembyld e tohu ana mo te reri mo te hanga rongoa Peptide
Te reri o te hanga rongoa peptide, ehara i te raraunga haumanu, i whakatauhia nga putanga ture e rua mo te ngota ngota kotahi. I whakaaetia e te FDA a Isembyld (apitegromab-mstn) i runga 11 Hepetema 2026 mo te atrophy uaua i roto i nga pakeke me nga tamariki pakeke 2 me te pakeke ake i runga i te maimoatanga SMN2. Rua tekau ma iwa nga ra o mua, kua tangohia te tono a te EU.
Ko te kore i puta tuatahi mai. I te marama o Hepetema 2025 i tukuna e te FDA he Reta Whakautu Katoa e whakahua ana i nga raruraru tautukunga i tetahi kaihanga tuatoru, me nga whakahee e e pa ana ki te waahi whakangao, kaua ki nga korero whaihua, haumaru ranei. Ko te tirohanga a Isembyld a EMA e tuhi ana i te tangohanga 13 Akuhata 2026: karekau te pae i whakaatu i te hanganga ture o te EU GMP i roto i te waa e hiahiatia ana. Whai muri i te whakarōpūtanga o nga mahi whai mana, i tukuna e te kaitautoko taua waahi mai i te tono a te US, a ka whakaaetia e te FDA.
Kotahi te whakatikatika i mua i te akoranga. Ko te ISEMBYLD he antibody monoclonal IgG4 tino tangata e herea ana te promyostatin me te myostatin huna., ehara i te peptide waihanga. Ko te panui a te FDA kaore rawa e whakamahi i te reo tikanga. He aha nga whakawhitinga ki te peptide me nga tikanga e pa ana ki te peptide ko te whakatikatika, ehara i te rāpoi ngota.
He aha i whakatauhia e te Riri o te Pae te uru ki te maakete i mua i te mahi a te Pūtaiao
Ko te 2025 Ko te reta whakautu katoa kaore i patai mena he mahi te rongoa. I whakahuahia nga raruraru hanganga ture i tetahi kaihanga tuatoru, i korerohia e te kamupene he hononga ki te waahi whakangao, kaua ki nga raraunga whaihua, haumaru ranei (Ko te korero a BioSpace mo te whakaaetanga).
Ko te waahi e pa ana ki te whakaingoatia i waho o nga wharangi ake o te kaiwhakahaere. Ko te tirohanga a Isembyld a EMA kaore i te tautuhi i te whare, i te wa he tātaritanga ture-GMP o te tangohanga e tohu ana ki te whare rongoa-whakakii me te whakakī-whakaoti a Catalent Indiana, whakahua a 2025 Reta Whakatupato FDA me a 2026 Puka 483 e hipoki ana i te tātari take pakiaka, te waikura me te poke, ka whakakiia te pāpāho, tūponotanga aukati, me te tirohanga tirohanga.
Ko te tauhanga te tautohe. Tekau ma tahi marama i wehe te turanga tuku mai i te tangohanga a te EU, tata ki te tekau ma rua marama ki te whakaaetanga a te US, a 29 nga ra i waenganui i nga putanga e rua (Ko te korero a BioSpace mo te whakaaetanga).
Mo te hanga peptide GMP, ka whakawhiti tika te akoranga: he pae whakakī, hua tarukino ranei e kore e taea te whakawātea i te tirotiro GMP he morearea te uru atu ki te maakete i runga i te maamaa o te API..
Ko te Rautaki Whakahaere Huanga-Ono mo te Ririri Hangahanga Hauora Peptide
Me whai i enei huanga e ono hei rautaki mana wetewete kotahi, kaua e ono pouakataki. Tuakiri, te parakore me te ahua poke, te whakahiato me te hanganga teitei, kaha, te whakataurite i muri i te huringa tukanga, me te tuku i nga whakamatautau ka aukati i etahi atu. Ko te kaupapa e whakamana ana i a raatau takitahi ka uru ki nga whakamatautau takitahi, ka taka tonu te whakataurite i te wa ka huri te tukanga ki nga whenua.
Ko te huinga huanga ehara i te mea tenenga peptide. Ka taka nga rongoa peptide ki roto i tetahi, neke atu ranei nga waahanga ture, hei rāpoi ngota matū tikanga, hinonga koiora, biosimilars ranei, me nga kaupapa QC i tuhia mo ratou te whakaingoa i te tohu koiora, hanganga teitei-tono, whakahiatotanga, tātari herenga disulfide, me te tātari poke e pa ana ki nga hua hei rarangi huanga mahi (Ko nga ihirangi tautoko a BioProcess International, 2020). Ko tera rarangi te take kei konei te whakahiato me te hanganga raupapa teitei: Ko te whakaaro noa kaore e pa ana ki nga peptides ka whakahēhia e te huinga huanga ake.
Whakamahia nga waahanga e whai ake nei hei piro i to ake hotaka. Kei ia tangata te take e whai take ai te huanga, me pehea te whakatinana, he aha te ahua o te kore, me tetahi tauira mahi.
tuhi tuhi: Ka whakawhānuihia tenei anga ki nga peptides ma te whakataurite mai i te keehi antibody monoclonal. Ko te whakataurite te kaupapa, ehara i te kereme o mua.
Te Whakamatau Tuakiri: Te Whakamatau i te Raupapa, Ehara i te Peak anake
Ko te tihi matua kotahi i te wa pupuri e tumanakohia ana ehara i te tuakiri. He rereke te patai a te whakamatautau tuakiri peptide i nga whakautu a te rohe: koinei te raupapa i tukuna e koe, tetahi mea ranei e hono tahi ana ki a ia?
Ko nga poke ka puta i te haki-a-rohe he maha nga wa ka mau te hainatanga papatipu kua tautuhia. E ai ki he kaiwhakamarama tohu peptide-parakore, ko te tapahi ka ngaro nga toenga N-terminal i muri i te rahua o te huringa hono, i te mea ka tangohia e te whakakorenga tetahi toenga o roto ka hono tahi hei tihi peerangi. Ka huri te hāora i te papatipu mā +16 Da hei Met-sulfoxide (Cys i +16/+32/+48 Na) me te tikanga elutes 1 ki 3 meneti i mua. Ko nga toenga whakamarumaru ka taapirihia te t-Bu +56 Da ko Fmoc ranei +222 Na, ka noho a pGlu ki −17/−18 Da.
Ka pakaru katoa nga Diastereomers i te tautohetohe papatipu: he rite tonu te papatipu ki te peptide kua tapaina. Koia te take kaore i te rawaka te whakapumautanga papatipu anake, ka tino mahi te orthogonality chromatographic.
Whakahoahoa HPLC-waahanga whakamuri (RP-HPLC) me LC–MS/MS (chromatography wai–tandem mass spectrometry), katahi ka taapirihia he hikoi maataki ahuru, orthogonal ranei i nga waahi e tika ana te mate diastereomer.
Kei te ata noho te aratau rahunga: he whakaritenga tuku e tuku ana i te paiheneti o te rohe i te wa e kawe ana te peerangi whakakorenga tahi ki te whare haumanu..
Te Purity me te Pure Profile: Te Aritmetika Hononga-Kakama
Ko te taumahatanga poke i roto i te peptide waihanga ka whakatauhia i mua i te tiimata o te purenga, na te mea ka waiho e ia huringa hono he hautanga o nga mekameka kei muri. He kaiwhakamarama whakaahua peptide-parakore e whakaatu ana i te RP-HPLC mo ia huringa SPPS te pai o te hono hono o te 99.0–99.8%, me te tuhipoka e i 99.5% ia huringa i runga i te 25-mer, āhua 12% o nga hua kua kohia kua ngaro, Ko tetahi waahanga ka puta he tihi tapahi motuhake (Lyochem Lab Notes, 2026-05-25). Ko taua puna he kaihoko e whakaatu ana i ana ake mahi tohu, no reira, kia rite ki te wheako whakahaere o te taiwhanga kotahi, kaua ki te tuunga ahumahi.
E kii ana te puna ano i nga paepae purongo e hono ana ki te ICH Q3A 0.05% i te horopeta mōrahi rā o 2 g/ra iti iho ranei, me nga paepae tautuhi i te nuinga o te 0.10–0.15% (Lyochem Lab Notes, 2026-05-25). Manatokohia nga mea e rua ki te kuputuhi ICH Q3A tuatahi i mua i te tuhi i aua mea ki roto i tetahi korero.
Taketake Matua： Ko te aratau kore i konei ko te peptide parakore me te whakakitenga mo te pokenga i hangaia i runga i te paepae kaore he tangata i tirohia ki te tuhinga ICH tuatahi. Whakapumautia te purongo o naianei me nga rohe tautuhi i te puna, katahi ka whakatauhia o ake rohe ki te whai huatanga o to huarahi mo ia huringa.
Te Whakakotahitanga me te Hanganga Whakanui-a-Teitei: Ka He te Huanga Peptides
Ko te whakahiato me te hanganga teitei ake kei roto i te rautaki whakahaere peptide mai i te timatanga, me te whakaaro karekau ratou ko te aratau kore. Ko te huinga huanga QC kua whakaingoatia mo nga peptides kei roto i nga ahuatanga koiora, hanganga teitei-tono, whakahiatotanga, me te wetewete herenga-waukawa, e tuu ana te mana whakahiato peptide ki te taha o te tuakiri me te ma, kaua ki muri (BioProcess International, ihirangi tautoko).
Ko te whakatau whakatinana ko nga tikanga koiora hei tohu, a kei roto i a koe ake tohu tikanga, kaua ki te roopu antibody i namahia. Ko te keu mo te taapiri he raima: te roa o te raupapa, ihirangi disulfide, me te rahi o tetahi totoro hydrophobic. Ko te peptide raina poto kaore he cysteinees e tino hiahia ana ki te huinga katoa. He raupapa roa me nga disulfides maha, he paraka hanga peptidic ranei e mau ana i te wahanga hono, mahi, na te mea ka huri te conjugate i te mata whakahiato.
Te Kohanga Peptide Ko te aratau rahunga he wa. Ka kitea he take whakahiato, he take hangarite ranei i te wa o te whakataurite, i muri i te huringa tukanga, a kua ngaro ke atu nga korero hei whakatau. Hangaia te tikanga kua whakaritea i mua i te huringa, kaore i muri.
Te Whakatairanga Kaha: Te Whiriwhiri i tetahi Tikanga Ka Ora i te Huringa Tukanga
Whiriwhiria te tikanga kaha mo tona aro ki te huringa ka tino mahia e koe, ehara i te mea he pai ki te tuku. Ko te whakamatautau kaha peptide e whakau ana kei te noho tonu te ngota ngota e kore e taea te kawe i te tautohe whakataurite i muri i te waahi, i te huringa tauine ranei, na te mea kare ano i hanga hei rehita i te nekehanga me whakaahua e koe inaianei.
Ko te panui hono-a-tinana te timatanga. Me ine te whakamatautau i runga i te pūtau, i te here ranei i te hikoinga ka raru pea to huringa tukanga, ahakoa he pai te hono, he takahanga takai, he poke ranei e whakataetae ana ki te whainga. Whakauruhia ki te paerewa tohutoro i mua i te huringa tona tohu, me te tuhi i te take o nga paearu whakaae i mua i te whakamanatanga o te wahanga-tika, kaua i muri i te rahua o te puranga tuatahi.
The failure mode is variability wide enough to swallow a real effect. If the assay’s own noise band is broader than the potency shift a scale change produces, a genuine decline reads as normal variation, and the comparability package has no signal to argue from.
A program moving from a 50 L to a 500 L fermentation train shows how this plays out. The larger vessel shifted the impurity profile, but the potency Peptides Hangaia method had never been qualified to detect that shift, so the team could show the product was present without being able to show it was equivalent.
Whakatauritenga I muri i te Huringa Tukanga: Tatau Pukana, Wā, me te Ora Papa
Ratonga Comparability after process change is a batch-count and timing decision, and both parts are usually settled too late to be useful. The FDA comparative-analysis document sets an expectation of at least 3 test batches for impurity, whakahiatotanga, me te whakatairite mate-mate, i te iti rawa 2 he maha nga raau taero i roto i te hua whakamatautau, me te iti rawa 3 he maha nga reanga rereke kua tohua hei tohutoro (Tuhinga whakataurite-tātari FDA). Ko tetahi whakatupato kei runga i te wharangi, kaua i te tuhipoka: Ko taua puna he PDF karekau ona tuhinga e taea te panui takitahi i konei, no reira ko enei whika e mau ana i te whakarāpopototanga whārangi-pānui anake, ā, me taki ki te tuhinga tuatahi i mua i te haere ki roto i te konae e anga ana ki te tuku..
Ko nga whakamatautau ka mutu i te tukunga ka ngaro i te huarahi whakaheke ka taea e te whakarereketanga o te waahi te whakarereke, no reira me tuku te kete me nga raraunga mutunga-o-papa-ora. He mea nui ano te waa. Ko te korero a BioSpace mo te whakaaetanga e whakaatu ana he aha te mea ka puta mai te raru o te waahi i muri i te tukunga: me puta katoa te pae mai i te tono. Hanga Peptide
Mo te Aki: Ko nga tatauranga o te puranga i runga ake nei kei te noho engari kaore i te whakapumau takitahi i runga i tenei turanga. Manatokohia ki te tuhinga tuatahi a te FDA i mua i te whakahua i a raatau i roto i tetahi tuhinga e anga ana ki te tuku.
Tukuna te Whakamatau me te Rarangi Whakataunga Moving
Ko nga tumanakohanga rautaki-whakahaere mo nga peptides waihanga tino purea kei te neke haere i te ra whakaae, no reira me mahi ano te tohu whakamatautau tuku peptide i tenei ra i mua i te mahi. Kei runga 28 Hōngongoi 2026, te FDA whakaputaina 17 kua whakahouhia nga aratohu hua-hua mo etahi hua peptide whanui me te tango i tetahi aratohu na te mea "kaore e whakaata[ing] Te whakaaro pūtaiao o naianei a FDA,” mo ia Ko te korero a te FDA mo nga aratohu peptide kua whakahoutia. Ko te tuhinga i tangohia ko te Mei 2021 arataki synthetic-peptide, a e kii ana te tari kei te whakaaro ia ki te whakahou me te whakaputa ano i tenei tau, e ai ki te panui Rehita Federal.
Ko te 17 he ngawari te panui i te tatau. Ko nga rarangi panui a Federal Register 9 kai kaha kei muri i era 17 nga aratohu kua whakahoutia: hāmana calcitonin, dasiglucagon HCl, glucagon, liraglutide, pegcetacoplan, semaglutide, teriparatide, tirzepatide, me te vosoritide.
|
Ko nga tauira PSG kua whakahoutia |
Kua whakarārangitia ngā kai kaha |
|---|---|
|
17 |
Toa 9 |
Ko te kaute na te hua tarukino, ehara ma te whakauru kaha.
Me whai i te aratohu kua tukuna ano hei keu korero-whakarereke. Hangaia te paewhiri tuku kia kore ai te huringa paepae e whakakore i te huinga tikanga katoa. Ko te aratau rahunga he panui i hangaia mo nga whakaaro o te kaiarahi kua tangohia.
He aha te mahi a tenei keehi me te kore e ako ki nga Kaihanga Peptide
Ko te akoranga ka taea te whakawhiti mai i te keehi Isembyld ko te waahi me te reri o te kounga he mea tino nui ki te tuku., ehara i te awangawanga whakahaere o raro. E wha nga akoranga ka whai mai i tera, me tetahi rohe pono.
Whakaritehia te pae i mua i to konae. I ngaro te dossier i tana tono EU ki te rohe wa GMP kaua ki ana raraunga, na ko te mahi reri kei runga i te huarahi tino nui, kaua i muri mai.
Kaua e whakaaro ko te whakahiato me te hanganga teitei ake he peptide-kore. Ko te huanga tera pea ka iti te hanga, a kua whakaingoatia ki te huinga huanga peptide QC.
Manatokohia nga tatauranga o te paepae me te tatauranga puranga ki nga tuhinga tuatahi. Ko te kapinga tuarua ka tohatoha i nga nama karekau e ora i te haki ki te puna, ko te aha tenei tuhinga i taratahi ai tetahi huinga tau toha.
Me mahi nga huanga e ono hei rautaki whakahaere kotahi. Ko te whakataurite te waahi ka kore nga kaupapa huanga momotu.
Te rohe: Ko ISEMBYLD he antibody monoclonal, no reira he whakatairite rite tenei ki nga peptides me nga tikanga e pa ana ki te peptide, ehara i te peptide-whakaaetanga o mua.
Te taahiraa o muri: piro taau ake hotaka ki nga huanga e ono, ka whakaūhia te paepae onāianei me te rarangi tatau-a-puranga ki nga tuhinga tuatahi i mua i to tukunga ki te ra tuku. Ko nga Huringa MOL e tautoko ana i te reri o te hanga rongoa peptide na roto i te waahanga totoka me te whakahiato moroiti., Karaehe 100 nga mahi horoi, me te HPLC, MS me te waikura QC, a ka taea te whakamahi ki te arotake i tetahi rautaki whakahaere tātari ki nga huanga o runga ake nei. Ko nga whakatau kaupapa-a-kaupapa e hiahia ana ki nga tohungatanga mana whakahaere me te kounga.
Pātai Auau
Ka mahi tenei anga rite mo te kaupapa peptide iti ake?
Ae, me te kete taunakitanga kua kopaki. Ka taea e te kaupapa kaore he mahi CMC whakatapua ki te whakahaere i nga huanga e ono katoa, engari me whirinaki ki nga raraunga papaa me te whakaputa tikanga mahi kaua ki te whakaputa i tana ake huinga whakamana mo ia huanga. Ko te angamahi kaore he roopu nui; ka whakaarohia ko te whakamatautau tuakiri peptide, mā, whakahiatotanga, kaha, te whakataurite, me te tuku whakamatautau kei ia tangata he rangatira ingoa me tetahi tikanga kua tuhia, ahakoa he maha nga mahi a te tangata kotahi. Ko te aratau rahunga ehara i te roopu iti. He huanga karekau he rangatira tae noa ki te wa kati tuku tuku.
He aha te utu mo te putea whakataurite i roto i nga puranga me te waa?
Putea mo nga whakamatautau tuku me nga whakamatautau mutunga-o-papa-ora mo nga mea e rua i mua i te huringa me te whakarereketanga, ko te tikanga kia toru nga roopu mo ia taha me te matapihi pumau i whanganga i roto i nga marama, ehara i nga wiki. Ko te tatauranga tika o te puranga ka whakawhirinaki ki to tukanga me to kaiwhakahaere, no reira tirohia nga whika ki runga i te aratohu tuatahi, kaua ki te whakarapopototanga. Ko te aratau rahunga i konei ko te raupapa: He maha nga wa ka timata nga roopu ki te whakarereke i te tukanga i mua i te tuhi i te kawa whakataurite, katahi ka kitea ko nga tikanga wetewete kaore e taea te whakatau i te rereketanga me whakaatu.
He aha taau mahi rereke mai i te keehi Isembyld?
Whakaritehia te waahi i mua atu, tautuhi i te tikanga biophysical kua whakaritea i mua i te huringa o te tukanga tuatahi, me te panui i nga paepae i roto i nga tuhinga tuatahi, kaua i nga korero hokohoko. Ko te patai o te waahi ehara i te korero mo te hangahanga ka mutu te mutunga; he mea keeti ka taea te whakatau i te urunga o te maakete i runga i te maatauranga. Ko te rongoa i te reri o te hanga rongoa peptide hei tuku i te taumata o te kaupapa, nona mai i te timatanga, Ko te rereketanga i waenga i te konae ka neke me te mea e tatari ana.
Whakamutunga
Ko te reri o te hanga rongoa Peptide ehara i te mahi tuhinga ka oti i a koe kotahi; he rautaki whakahaere e piro tonu ana koe. Ko te keehi a Isembyld e hanga ana i taua raima. Ko taua ngota ngota, i arotakehia e nga kaiwhakahaere e rua, i puta nga hua e rua, a ko te taurangi i neke ko te pae: i whakahuahia e te FDA nga raruraru hanganga ture i tetahi kaihanga tuatoru, a ka tukuna katoatia e te kaitautoko tera waahi mai i tana tono (Ko te korero a BioSpace mo te whakaaetanga). I tangohia te tono a te EU 13 Akuhata 2026 na te mea kaore te pae i whakaatu i te hanganga ture o te EU GMP i roto i te waa e hiahiatia ana (Ko te tirohanga a Isembyld a EMA). Rua tekau ma iwa nga ra e wehe ana i nga whakatau e rua. Mō
Tohua taau ake kaupapa ki nga huanga e ono ka kimihia te mea kaore ano koe e whakaatu. Ko taua huanga ka whakatau i to tuanui. Manatokohia ia paepae, tatau puranga, me te tohutoro aratohu ki te tuhinga tuatahi i mua i te urunga ki tetahi taonga e anga ana ki te tuku.
Kotahi te rohe me whakahoki ano: Ko ISEMBYLD he antibody monoclonal IgG4 tino tangata, ehara i te peptide (te panui whakaaetanga a te kaitautoko). Ka whakawhiti te rautaki whakahaere; e kore te tikanga.
Tohua to hotaka i mua i to tohu tohu e whai ake nei Kawea mai to rarangi aputa huanga e ono ki te arotake hangarau o to rautaki whakahaere tātari, hipoki tuakiri, mā, whakahiatotanga, kaha, te whakataurite me te whakamatautau tuku, me panui ki te wahi e tino kikokore ana o taunakitanga. Korero ki tetahi tohunga
Ko nga Huringa MOL e whakarato ana i te tautoko tātari me te hanga mo nga kaupapa peptide. Ko nga whakatau e pa ana ki tetahi kaupapa rongoa motuhake e hiahia ana nga tohunga whakahaere me te kounga.
